Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

ClinicalTrials.gov ID: NCT00649025

Public ClinicalTrials.gov record NCT00649025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (250ug Twice Daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients With Moderate to Severe Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler. The purpose of this study is to determine how well your asthma is controlled when taking one of the three treatment.

Study identification

NCT ID
NCT00649025
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
SkyePharma AG
Industry
Enrollment
438 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2008
Primary completion
Sep 30, 2008
Completion
Sep 30, 2008
Last update posted
Aug 26, 2010

2008

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Investigational site Scottsdale Arizona 85251
Investigational Site Tempe Arizona 85282
Investigational Site Encinitas California 92024
Investigational site Long Beach California 90806
Investigational site Orange California 92869
Investigational Site Oldsmar Florida 34677
Investigational Site Indianapolis Indiana 46208
Investigational site Crestview Hills Kentucky 41017
Investigational Site Metarie Louisiana 70006
Investigational site North Dartmouth Massachusetts 02747
Investigational Site Wellesley Hills Massachusetts 02481
Investigational site Elizabeth City North Carolina 27909
Investigational Site Akron Ohio 44313
Investigational site Cincinnati Ohio 45227
Investigational Site Portland Oregon 97213
Investigational Site East Providence Rhode Island 02914
Investigational site Providence Rhode Island 02906
Investigational Site Austin Texas 78750
Investigational site El Paso Texas 79925
Investigational site Richmond Virginia 23229
Investigational Site West Allis Wisconsin 53227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.

Recently updated Asthma trials

Other public records listing Asthma. Sorted by last update posted; newest first. Not a recommendation.

All Asthma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00649025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 26, 2010 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00649025 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →